Genentech seeks expanded FDA approval for Avastin

12/3/2007 | Bloomberg

Genentech has applied for regulatory approval to market Avastin as a treatment for breast cancer. The move follows a successful clinical trial of Avastin, in which 722 breast cancer patients who took the drug with the chemotherapy agent paclitaxel had stable tumors for an average of 11 months, compared to six months in the control group. FDA advisers are scheduled to meet Wednesday to consider the company's request.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC